Edwards Lifesciences (EW) Common Equity (2009 - 2026)

Edwards Lifesciences has reported Common Equity for 18 years, with the latest figure at $10.7 billion in Q2 2026.

• On a quarterly basis, Common Equity rose 1.12% year-over-year to $10.7 billion in Q2 2026; TTM through Jun 2026 was $10.7 billion, a 1.12% increase from a year earlier, with the FY2025 full-year figure at $10.3 billion, up 2.73% from the prior year.
• Common Equity was $10.7 billion for Q2 2026 at Edwards Lifesciences, up from $10.3 billion in the prior quarter.
• The five-year high for Common Equity was $10.7 billion in Q2 2026, with the low at $5.8 billion in Q4 2022.
• Average Common Equity over 5 years is $8.1 billion, with a median of $7.3 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Common Equity dropped 0.5% in 2022, then jumped 49.76% in 2024.
• Over 5 years, Common Equity stood at $5.8 billion in 2022, then grew by 15.72% to $6.7 billion in 2023, then jumped by 49.76% to $10.1 billion in 2024, then increased by 2.73% to $10.3 billion in 2025, then climbed by 3.75% to $10.7 billion in 2026.
• The last three Common Equity figures came in at $10.7 billion (Q2 2026), $10.3 billion (Q1 2026), and $10.3 billion (Q4 2025), per Business Quant data.